Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms

Jason T Lerner1, Noriko Salamon2, Raman Sankar1,31Departments of Pediatrics, 2Radiological Sciences, 3Neurology, David Geffen School of Medicine, University of California Los Angeles and Mattel Children&rsquo;s Hospital at UCLA, Los Angeles, CA, USAAbstract: Vigabatrin, the first therapeutic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jason T Lerner, Noriko Salamon, Raman Sankar
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/3d72d9adf5de4e4cb3c10c2c6ecb8ce3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3d72d9adf5de4e4cb3c10c2c6ecb8ce3
record_format	dspace
spelling	oai:doaj.org-article:3d72d9adf5de4e4cb3c10c2c6ecb8ce32021-12-02T08:53:51ZClinical profile of vigabatrin as monotherapy for treatment of infantile spasms1176-63281178-2021https://doaj.org/article/3d72d9adf5de4e4cb3c10c2c6ecb8ce32010-11-01T00:00:00Zhttp://www.dovepress.com/clinical-profile-of-vigabatrin-as-monotherapy-for-treatment-of-infanti-a5599https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Jason T Lerner1, Noriko Salamon2, Raman Sankar1,31Departments of Pediatrics, 2Radiological Sciences, 3Neurology, David Geffen School of Medicine, University of California Los Angeles and Mattel Children&rsquo;s Hospital at UCLA, Los Angeles, CA, USAAbstract: Vigabatrin, the first therapeutic agent to be approved by the Food and Drug Administration for the treatment of infantile spasms, as well as for adjunctive use in the treatment of refractory complex partial epilepsy, represents an important advance for patients with difficult-to-manage epilepsy. This review summarizes the complex history, chemistry, and pharmacology, as well as the clinical data leading to the approval of vigabatrin for infantile spasms in the US. The long path to its approval reflects the visual system and white matter toxicity concerns with this agent. This review provides a brief description of these concerns, and the regulatory safety monitoring and mitigation systems that have been put in place to enhance benefit over risk.Keywords: vigabatrin, infantile spasms, monotherapy Jason T LernerNoriko SalamonRaman SankarDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 731-740 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Jason T Lerner Noriko Salamon Raman Sankar Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms
description	Jason T Lerner1, Noriko Salamon2, Raman Sankar1,31Departments of Pediatrics, 2Radiological Sciences, 3Neurology, David Geffen School of Medicine, University of California Los Angeles and Mattel Children&rsquo;s Hospital at UCLA, Los Angeles, CA, USAAbstract: Vigabatrin, the first therapeutic agent to be approved by the Food and Drug Administration for the treatment of infantile spasms, as well as for adjunctive use in the treatment of refractory complex partial epilepsy, represents an important advance for patients with difficult-to-manage epilepsy. This review summarizes the complex history, chemistry, and pharmacology, as well as the clinical data leading to the approval of vigabatrin for infantile spasms in the US. The long path to its approval reflects the visual system and white matter toxicity concerns with this agent. This review provides a brief description of these concerns, and the regulatory safety monitoring and mitigation systems that have been put in place to enhance benefit over risk.Keywords: vigabatrin, infantile spasms, monotherapy
format	article
author	Jason T Lerner Noriko Salamon Raman Sankar
author_facet	Jason T Lerner Noriko Salamon Raman Sankar
author_sort	Jason T Lerner
title	Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms
title_short	Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms
title_full	Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms
title_fullStr	Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms
title_full_unstemmed	Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms
title_sort	clinical profile of vigabatrin as monotherapy for treatment of infantile spasms
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/3d72d9adf5de4e4cb3c10c2c6ecb8ce3
work_keys_str_mv	AT jasontlerner clinicalprofileofvigabatrinasmonotherapyfortreatmentofinfantilespasms AT norikosalamon clinicalprofileofvigabatrinasmonotherapyfortreatmentofinfantilespasms AT ramansankar clinicalprofileofvigabatrinasmonotherapyfortreatmentofinfantilespasms
_version_	1718398296262705152

Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms

Ejemplares similares